Semaphorin Contributes to Lung Cancer Treatment Resistance

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancer (NSCLC) in patients who have epidermal growth factor receptor (EGFR) mutations. However, when patients relapse, they usually develop TKI resistance. Scientists discovered a protein called semaphorin was a piece of the drug-resistance puzzle. In a study published in JCI Insight, researchers revealed a specific semaphorin called Semaphorin 7a (SEMA7A) as a target gene of EGFR mutations that plays a significant role in a...
Continue reading

Increased Life Expectancy in Stage IV ALK+ Lung Cancer

Historically, patients with stage IV anaplastic lymphoma kinase-positive (ALK+) lung cancer had a dismal prognosis; between the years 1995 and 2001, only 15% of those with this disease lived past 5 years of diagnosis. However, recent studies show that patients with this cancer have been living longer. In a study published in the Journal of Thoracic Oncology, investigators working for the University of Colorado Cancer Center determined that patients diagnosed with stage IV ALK+ non-small cell lun...
Continue reading

Atezolizumab Approved for Metastatic Nonsquamous NSCLC

After granting Priority Review, the FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.), a monoclonal antibody, to be used in combination with carboplatin/paclitaxel/bevacizumab (CPB) for patients with previously untreated metastatic nonsquamous, non-small cell lung cancer (NSCLC) without EGFR or ALK tumor mutations. The approval was based on the open-label, three-arm IMpower150 trial (NCT02366143), for which patients were randomized 1:1:1 to a regimen of atezolizumab plus CPB, a regimen...
Continue reading

Metastatic Non-Small Cell Lung Cancer: Academic Treatment Settings Improve Survival

Patients with metastatic non-small cell lung cancer (NSCLC) have higher chances of surviving if they are treated in academic medical centers rather than in community-based centers, according to a new study published in the Journal of Thoracic Oncology. Of the approximately 85% of lung cancer patients who are diagnosed with NSCLC, around 40% present with metastatic disease. Metastatic NSCLC is highly difficult to treat and leaves patients with limited chances of survival. However, new treatment s...
Continue reading

Durvalumab Improves Survival in Advanced Lung Cancer

A new study has demonstrated that durvalumab (Imfinzi®, AstraZeneca) improves survival for patients with stage III, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed after chemoradiotherapy. Durvalumab, an intravenously administered immune checkpoint inhibitor, was approved in February by the United States Food and Drug Administration (FDA) as a standard-of-care treatment for this indication. It works by blocking programmed cell death ligand 1 (PD-L1), a protein fo...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.